Zevra Therapeutics (ZVRA) Change in Acquisitions & Divestments (2016 - 2026)

Zevra Therapeutics' Change in Acquisitions & Divestments history runs 9 years deep, the most recent figure standing at $94.0 million for Q1 2026.

• Quarterly Change in Acquisitions & Divestments rose 422.07% year-over-year to $94.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $254.5 million (up 802.16% YoY) and the FY2025 annual result came in at $178.5 million, up 614.0% from the prior year.
• Change in Acquisitions & Divestments was $94.0 million for Q1 2026 at Zevra Therapeutics, up from $87.5 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $94.0 million in Q1 2026 and bottomed at $202000.0 in Q4 2024.
• A 5-year average of $29.4 million and a median of $14.8 million in 2024 frame the typical range for Change in Acquisitions & Divestments.
• Annual changes were most pronounced in 2024 — Change in Acquisitions & Divestments slumped 98.71% — and 2025, when it jumped 43216.83%.
• Zevra Therapeutics' Change in Acquisitions & Divestments stood at $300000.0 in 2022, then surged by 5108.33% to $15.6 million in 2023, then slumped by 98.71% to $202000.0 in 2024, then soared by 43216.83% to $87.5 million in 2025, then climbed by 7.4% to $94.0 million in 2026.
• Business Quant data shows ZVRA's Change in Acquisitions & Divestments at $94.0 million in Q1 2026, $87.5 million in Q4 2025, and $60.5 million in Q3 2025.